P-92 Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

Mehmet Artaç ,D Çevik,Abdullah Sakin ,Serhat Çelik ,Ahmet Bılıcı ,Timuçin Çil ,Ahmet Alacacıoğlu ,Oktay Bozkurt ,M Karaca ,Eda Tanrikulu Şimşek ,Çağlayan Geredeli ,Umut Kefeli ,Deniz Tural ,Hacı Mehmet Türk ,F Dane ,Nuri Karadurmuş ,Mehmet Ali Nahit Şendur ,Melike Özçelik ,Erdem Çubukçu ,Bala Başak Öven ,Hakan Harputluoğlu ,M Gümüş

doi:10.1016/j.annonc.2022.04.182

P-92 Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

Mehmet Artaç , D Çevik + Show 20 more

Open Access

https://doi.org/10.1016/j.annonc.2022.04.182

Copy DOI

#RAS Wild-type mCRC Patients #Advantage For Overall Survival + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim was to study the real-life experience (onco-colon registry Turkey) of maintenance chemotherapy with antiEGFR or antiVEGF mAbs after the standart firstline doublet chemotherapy backbone in RAS wild-type mCRC patients.

Full Text